Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 178 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]
2. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
3. Cita con resumen
Torvinen-Kiskinen S, Tolppanen A-M, Koponen M, Tanskanen A, Tihonen J, Hartikainen S, Taipale H. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease—a nested case-control study. Aliment Pharmacol Ther 2018;47:1135-42. [Ref.ID 102491]
4. Cita con resumen
Liou J-M, Fang Y-J, Chen C-C, Bair M-J, Chang C-Y, Lee Y-C, Chen M-J, Tseng C-H, Hsu Y-C, Lee J-Y, Yang T-H, Luo J-C, Chang C-C, Chen Y-N, Sheu B-S, Lin J-T, Wu J-Y, El-Omar EM, Wu M-S, Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016;388:2355-65. [Ref.ID 100981]
5. Cita con resumen
Anónimo. Comparative effectiveness of proton pump inhibitors. Therapeutics Initiative Evidence Based Drug Therapy 2016;99:1-2. [Ref.ID 100573]
6.Tiene citas relacionadas Cita con resumen
Kuller LH. Do proton pump inhibitors increase the risk of dementia?. JAMA Neurology 2016;73:379-81. [Ref.ID 100322]
7.Tiene citas relacionadas Cita con resumen
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology 2016;73:410-6. [Ref.ID 100299]
8.Enlace a cita original Cita con resumen
Begley J, Smith T, Burnett K, Strike P, Azim A, Spake C, Richardson T. Proton pump inhibitor hypomagnasemia - a cause for concern?. Br J Clin Pharmacol 2016;81:753-8. [Ref.ID 100179]
9. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
10. Cita con resumen
Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]
11. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
12. Cita con resumen
Anónimo. Which PPI?. Med Lett Drugs Ther 2015;57:8-9. [Ref.ID 99216]
13. Cita con resumen
Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015:10 de junio. [Ref.ID 99197]
14.Enlace a cita original Cita con resumen
Drago F, Javor S, Ciccarese G, Cozzani E, Parodi A. Subacute cutaneous lupus erythematosus induced by lansoprazole. Eur J Clin Pharmacol 2015;71:767-8. [Ref.ID 99181]
16.Tiene citas relacionadas Cita con resumen
Anónimo. Acide tranexamique et thromboses (suite). Prescrire 2013;33:276-7. [Ref.ID 95343]
17.Tiene citas relacionadas Cita con resumen
Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Buttò V, Ferrucci L, Bandinelli S, Abbatecola AM, Spazzafumo L, Lattanzio F. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013;173:518-23. [Ref.ID 95257]
18.Tiene citas relacionadas Cita con resumen
Liou J-M, Chen C-C, Chen M-J, Chen C-C, Chang CY, Fang Y-J, Lee J-Y, Hsu S-J, Luo J-C, Chang W-H, Hsu Y-C, Tseng CH, Tseng PH, Wang H-P, Yang U-C, Shun CT, Lin J-T, Lee Y-C, Wu M-S, for the Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13. [Ref.ID 94796]
19.Tiene citas relacionadas
Greenberg ER, Chey WD. Defining the role of sequential therapy for H pylori infection. Lancet 2013;381:180-2. [Ref.ID 94793]
20.Enlace a cita original Cita con resumen
Madrilejos R. Inhibidors de la bomba de protons i el balanç risc/benefici. Butlletí d'Informació Terapèutica 2013;24:7-11. [Ref.ID 94629]
Seleccionar todas
 
 1 a 20 de 178 siguiente >>